BioCentury
ARTICLE | Company News

Bavarian Nordic, U.S. Department of Health and Human Services infectious news

April 28, 2014 7:00 AM UTC

Bavarian Nordic said HHS's Biomedical Advanced Research and Development Authority (BARDA) exercised an option to award $21.9 million under a 2009 contract to develop a freeze-dried formulation of Imvamune smallpox vaccine. The company said the freeze-dried formulation could have a longer shelf life than the liquid frozen formulation and would not require cold-chain handling (see BioCentury, Nov. 23, 2009).

BARDA exercised the option after the company completed enrollment of 680 healthy volunteers in a Phase II trial to support emergency use of the freeze-dried formulation in the U.S. Bavarian Nordic plans to submit the data to FDA next year for potential production and supply to begin in 2016, which would require a new government contract. ...